Warfarin Sensitivity Genotyping
CYP2C9 Association Study
August 2008
In an association study, preformed recently, they found that the risk for a major hemorrhage due to having CYP2C9 polymorphic alleles increased markedly with a hazard ratio of approximately 3. The risk for a major bleed with CYP2C9 variant allele was 5.3-fold higher than normal before stabilization of therapy in the warfarin induction period and this risk was maintained at 2.2-fold risk after stabilization of the warfarin dosing.
Intracranial bleeds are a minimum of between an INR of 2-2.5. Warfarin therapy related deaths minimized between an INR of 2-2.5 and at an INR of greater than 2.5 the death rate increases 2.3-fold per unit increase in INR. Warfarin has the greatest number of deaths of all drugs from death certificates, so it is important to be able to identify individuals who are at a higher risk for these related problems with warfarin by doing genotyping.
CYP2C9 Association Study |
Jump to section:
- Introduction
- Warfarin
- Warfarin Anticoagulation
- Warfarin
- Warfarin Monitoring
- Therapeutic Graph
- INR Variability in a 74 Year-old Male
- Warfarin and Bleeding Events
- Warfarin Metabolism
- Polymorphisms and Warfarin Sensitivity
- Polymorphisms and Warfarin Sensitivity
- Summary of Polymorphisms and Warfarin Pharmacokinetics5
- CYP2C9 Association Study
- PGx-Guided Warfarin Dosing7
- Warfarin Pharmacodynamics
- Polymorphisms and Warfarin Sensitivity
- VKORC1 Promoter Polymorphism6
- CYP2C9 and VKORC1 Interaction8
- Genotype-guided Warfarin Dosing9
- Genotype-guided Dosing
- Summary
- Orthopedic Algorithm10
- Significant Warfarin Drug Interactions
- Differential Effect of Drugs
- Patient Case: Rapidly Increasing INR
- References
- Questions?
External
link
PDF
document
Excel
document
Word
document